India's Strides Shasun has been expanding and will add a seventh manufacturing site to its operations in Africa after buying controlling interest in a Kenyan drug producer.
Melbourne-based venture capital fund Brandon Capital Partners has opened a Palo Alto office, hiring a veteran as a partner as part of its aim to bring promising Australian pharma and medical tech to the market.
Two Indian companies are set to roil the global market for hepatitis C drugs further, calling into question spending and approval paces by Japan, Australia and the U.S. among others, while China, the potential top market, slowly grinds through clinical and regulatory processes.
FiercePharmaAsia 's Matt Driskill discusses the recent conference call held by Benitec Biopharma in Australia in which interim CEO Greg West explains the rather abrupt departure of CEO Peter French and outlines the company's search for a replacement who can bring deep experience in the American market.
Good news for Gilead Sciences and Bristol-Myers Squibb: Australia's federal government wants to eliminate hepatitis C in the country. And it plans to shell out $1 billion on the drugmakers' meds to do that.
The government of Australia said it will spend $1 billion over 5 years to provide "groundbreaking" treatments for hepatitis C sufferers and that it hopes the work will eliminate the disease from down under within a generation, according to a report by ABC News.
Vaccines are tricky products, hard to keep safe and sterile when shipped and stored under tough conditions. GlaxoSmithKline has now opened a pilot plant in Australia to see if its blow-fill-seal technology can do a better job with them.
An Australian court ruled that British drugmaker Reckitt Benckiser would have to pull its series of ibuprofen painkillers off the market within three months and pay a fine that could reach $800,000 per product. In addition, the company could still face regulatory rejections.
Australia's Mesoblast formally listed on the Nasdaq on Friday and rose 11 cents to $8.11 after offering nearly 8.54 million American Depositary Shares, including partial exercise of an overallotment option, the company said in a press release.
The government of Australia said it will no longer cover basic nonprescription drugs like paracetamol and aspirin which are among 17 basic medicines that will be removed from the country's Pharmaceutical Benefits Scheme starting in 2016. The move will save half a billion Australian dollars over the next 5 years, which Health Minister Sussan Ley said will be spent on listing new lifesaving drugs, according to a report in The Australian.